Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

UTHR

United Therapeutics Corp

Dec 13 • 04:00PM ET

361.81

Dollar change +0.20
Percentage change 0.06	%

Healthcare • Biotechnology • USA • NASD

Peers: AMGN PFE LLY MRK REGN JNJ BMY VRTX GILD BIIB

| Held by: VTI IJH VB VBR VXF COWZ XBI MDY IBB SPMD

Scroll to Statements

Index	-	P/E	15.89	EPS (ttm)	22.77	Insider Own	1.85%	Shs Outstand	44.62M	Perf Week	-2.13%
Market Cap	16.16B	Forward P/E	12.46	EPS next Y	29.04	Insider Trans	-34.92%	Shs Float	43.82M	Perf Month	-9.65%
Income	1.11B	PEG	1.17	EPS next Q	6.59	Inst Own	99.02%	Short Float	4.75%	Perf Quarter	4.88%
Sales	2.76B	P/S	5.86	EPS this Y	22.72%	Inst Trans	-5.54%	Short Ratio	6.22	Perf Half Y	25.60%
Book/sh	136.74	P/B	2.65	EPS next Y	19.44%	ROA	15.71%	Short Interest	2.08M	Perf Year	40.81%
Cash/sh	74.47	P/C	4.86	EPS next 5Y	13.64%	ROE	18.81%	52W Range	208.62 - 417.82	Perf YTD	64.54%
Dividend Est.	-	P/FCF	18.00	EPS past 5Y	8.15%	ROI	18.21%	52W High	-13.40%	Beta	0.56
Dividend TTM	-	Quick Ratio	4.41	Sales past 5Y	8.02%	Gross Margin	88.94%	52W Low	73.43%	ATR (14)	8.89
Dividend Ex-Date	-	Current Ratio	4.58	EPS Y/Y TTM	25.97%	Oper. Margin	46.42%	RSI (14)	42.09	Volatility	1.83% 2.59%
Employees	1168	Debt/Eq	0.07	Sales Y/Y TTM	25.04%	Profit Margin	40.31%	Recom	2.17	Target Price	395.83
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	18.61%	Payout	0.00%	Rel Volume	0.85	Prev Close	361.61
Sales Surprise	3.64%	EPS Surprise	-2.04%	Sales Q/Q	22.89%	Earnings	Oct 30 BMO	Avg Volume	334.91K	Price	361.81
SMA20	-1.60%	SMA50	-2.08%	SMA200	15.59%	Trades		Volume	286,109	Change	0.06%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-11-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$310 → $321
Feb-12-24	Upgrade	Goldman	Sell → Neutral	$213 → $215
Feb-05-24	Initiated	Leerink Partners	Outperform	$330
Dec-08-23	Initiated	Wells Fargo	Overweight	$309
Dec-06-22	Initiated	UBS	Buy	$320
Dec-05-22	Initiated	Goldman	Sell	$230
Oct-11-22	Initiated	Morgan Stanley	Overweight	$288
Sep-20-22	Reiterated	BofA Securities	Underperform
Sep-19-22	Resumed	Wedbush	Outperform	$263
Feb-11-22	Initiated	BTIG Research	Neutral
Jul-14-21	Upgrade	Argus	Hold → Buy	$205
Apr-26-21	Resumed	Credit Suisse	Outperform	$196
Feb-01-21	Upgrade	H.C. Wainwright	Neutral → Buy	$125 → $195
Sep-14-20	Resumed	JP Morgan	Overweight	$142
Jun-25-20	Reiterated	H.C. Wainwright	Neutral	$85 → $125
Mar-10-20	Upgrade	Jefferies	Hold → Buy	$123
Feb-27-20	Upgrade	Cowen	Market Perform → Outperform	$119 → $145
Jan-31-20	Upgrade	JP Morgan	Neutral → Overweight	$120
Dec-03-19	Initiated	BofA/Merrill	Underperform
Aug-01-19	Upgrade	Ladenburg Thalmann	Neutral → Buy	$103 → $106

Show Previous Ratings

Nov-29-24 11:32AM	Why Is United Therapeutics (UTHR) Up 1.1% Since Last Earnings Report? (Zacks)
Nov-05-24 04:30PM	United Therapeutics Corporation to Present at the UBS Global Healthcare Conference (Business Wire)
09:45AM	United Therapeutics (UTHR) is a Top-Ranked Growth Stock: Should You Buy? (Zacks)
Nov-04-24 09:40AM	United Therapeutics (UTHR) is a Top-Ranked Value Stock: Should You Buy? (Zacks)
Oct-31-24 04:46PM	Analyst Report: United Therapeutics Corporation (Morningstar Research)
03:08AM	Loading…
03:08AM	United Therapeutics Corp (UTHR) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
01:11AM	Decoding United Therapeutics Corp (UTHR): A Strategic SWOT Insight (GuruFocus.com)
12:10AM	Q3 2024 United Therapeutics Corp Earnings Call (Thomson Reuters StreetEvents)
Oct-30-24 09:30AM	Here's What Key Metrics Tell Us About United Therapeutics (UTHR) Q3 Earnings (Zacks)
07:40AM	United Therapeutics (UTHR) Q3 Earnings and Revenues Top Estimates (Zacks)
06:37AM	United Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
06:30AM	United Therapeutics Corporation Reports Third Quarter 2024 Financial Results (Business Wire)
Oct-29-24 09:15AM	Curious about United Therapeutics (UTHR) Q3 Performance? Explore Wall Street Estimates for Key Metrics (Zacks)
Oct-23-24 07:00AM	United Therapeutics Corporation Announces the 500th Lung Transplant Utilizing its Centralized Ex Vivo Lung Perfusion Service (Business Wire)
06:30AM	United Therapeutics Corporation to Report Third Quarter 2024 Financial Results Before the Market Opens on Wednesday, October 30, 2024 (Business Wire)
10:51AM	Loading…
Oct-18-24 10:51AM	Profitable Biotech In Buy Zone As Earnings Approach (Investor's Business Daily)
Oct-16-24 05:01PM	State Street Corp's Strategic Reduction in United Therapeutics Holdings (GuruFocus.com)
Oct-09-24 03:31PM	United Therapeutics Corp (UTHR) Q2 2024 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
07:56AM	Can United Therapeutics Corporation (UTHR) Capitalize on Record Revenue to Drive Future Growth? (Insider Monkey)
Oct-03-24 07:36AM	United Therapeutics Corporation (UTHR): Why Are Hedge Funds Bullish On This Cheap Growth Stock Right Now? (Insider Monkey)
Sep-24-24 07:00AM	United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the CHEST 2024 Annual Meeting (Business Wire)
Sep-21-24 09:22AM	United Therapeutics (UTHR) Is Thriving on Strong Demand and Smart Pricing (Insider Monkey)
Sep-10-24 07:00AM	United Therapeutics Publishes its 2024 Corporate Responsibility and Public Benefit Report Highlighting its Progress Toward a Future Where No Patient Gets Left BehindEver (Business Wire)
Aug-30-24 12:02PM	United Therapeutics Shares Thrive (FX Empire)
11:31AM	United Therapeutics (UTHR) Up 9.9% Since Last Earnings Report: Can It Continue? (Zacks)
Aug-28-24 07:00AM	United Therapeutics Corporation to Present at Upcoming Investor Conferences (Business Wire)
Aug-22-24 07:01PM	Insider Sale: Director Christopher Causey Sells Shares of United Therapeutics Corp (UTHR) (GuruFocus.com)
Aug-21-24 07:08PM	Analyst Report: United Therapeutics Corporation (Morningstar Research)
Aug-20-24 06:33AM	Liquidias YUTREPIA inhalation powder gains tentative FDA approval (Pharmaceutical Technology)
Aug-19-24 04:01PM	Why Liquidia Stock Just Reversed Its Seven-Day Sprint And Crashed 31% (Investor's Business Daily) +8.60%
07:01PM	Loading…
Aug-05-24 07:01PM	Insider Sale: Director Raymond Dwek Sells 5,000 Shares of United Therapeutics Corp (UTHR) (GuruFocus.com)
Aug-04-24 01:33PM	3 Biotech Stocks on Track for 50% Returns (or More) by 2028 (InvestorPlace)
Aug-02-24 12:00PM	United Therapeutics (UTHR) is a Great Momentum Stock: Should You Buy? (Zacks)
09:45AM	Here's Why United Therapeutics (UTHR) is a Strong Growth Stock (Zacks)
Aug-01-24 10:41AM	Stock Market Reverses Lower; Shake Shack, Meta Platforms Lead, But 3 Growth Stocks Hit Danger Zone (Live Coverage) (Investor's Business Daily)
01:06AM	Decoding United Therapeutics Corp (UTHR): A Strategic SWOT Insight (GuruFocus.com)
Jul-31-24 11:39PM	Analyst Report: United Therapeutics Corporation (Morningstar Research) -7.18%
04:14PM	IBD 50's United Therapeutics Slumps From Its Record High On Mixed Quarter (Investor's Business Daily)
12:45PM	3 Reasons Why Growth Investors Shouldn't Overlook United Therapeutics (UTHR) (Zacks)
09:51AM	United Therapeutics (UTHR) Q2 Earnings Lag, Sales Top Estimates (Zacks)
09:50AM	Here's Why United Therapeutics (UTHR) is a Strong Momentum Stock (Zacks)
09:30AM	United Therapeutics (UTHR) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks)
09:17AM	United Therapeutics Stock Skids On Mixed Second-Quarter Results (Investor's Business Daily)
07:40AM	United Therapeutics (UTHR) Misses Q2 Earnings Estimates (Zacks)
06:47AM	United Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
06:30AM	United Therapeutics Corporation Reports Second Quarter 2024 Financial Results (Business Wire)
Jul-30-24 09:40AM	Here's Why United Therapeutics (UTHR) is a Strong Value Stock (Zacks)
Jul-26-24 09:49AM	Implied Volatility Surging for United Therapeutics (UTHR) Stock Options (Zacks)
Jul-24-24 07:00AM	United Therapeutics Corporation to Report Second Quarter 2024 Financial Results Before the Market Opens on Wednesday, July 31, 2024 (Business Wire)
Jul-20-24 11:42AM	Meet some of the world's cleanest pigs, raised to grow kidneys and hearts for humans (Associated Press Finance)
Jul-17-24 09:45AM	Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term (Zacks)
Jul-15-24 09:04PM	3 Biotech Stocks to Buy Now: Q3 Edition (InvestorPlace)
12:45PM	Is United Therapeutics (UTHR) a Solid Growth Stock? 3 Reasons to Think 'Yes' (Zacks)
12:00PM	What Makes United Therapeutics (UTHR) a Strong Momentum Stock: Buy Now? (Zacks)
09:15AM	United Therapeutics Corporation (UTHR) Hit a 52 Week High, Can the Run Continue? (Zacks)
Jul-12-24 09:40AM	Why United Therapeutics (UTHR) is a Top Value Stock for the Long-Term (Zacks)
Jul-11-24 09:50AM	Why United Therapeutics (UTHR) is a Top Momentum Stock for the Long-Term (Zacks)
09:02AM	United Therapeutics (UTHR) Completes Enrolment in IPF Study (Zacks)
04:52AM	United Therapeutics TETON 2 study achieves full enrolment for IPF treatment (Clinical Trials Arena)
Jul-10-24 07:00AM	United Therapeutics Corporation Announces Full Enrollment of the TETON 2 Study of Inhaled Treprostinil for the Treatment of Idiopathic Pulmonary Fibrosis (Business Wire)
Jul-09-24 12:10PM	Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report? (Zacks)
Jul-08-24 11:23AM	3 Undervalued Stocks on Track to Double (or More) by 2028 (InvestorPlace)
Jul-01-24 02:18PM	7 Undervalued Biotech Stocks to Buy for Big-Time Returns (InvestorPlace)
Jun-28-24 10:36AM	Big Money Elevating United Therapeutics (FX Empire)
Jun-27-24 07:00AM	United Therapeutics Corporation Announces Election of Jan Malcolm to its Board of Directors (Business Wire)
Jun-26-24 03:02PM	Why United Therapeutics, An IBD 50 Stock, Has Surged 36% Over Nine Weeks (Investor's Business Daily)
09:40AM	Here's Why United Therapeutics (UTHR) is a Strong Value Stock (Zacks)
Jun-21-24 03:10AM	Insider Sale: Director Christopher Causey Sells Shares of United Therapeutics Corp (UTHR) (GuruFocus.com)
Jun-20-24 03:58PM	The 3 Best Medical Device Stocks to Buy in June 2024 (InvestorPlace)
Jun-18-24 07:00PM	Insider Sale: Director Judy Olian Sells Shares of United Therapeutics Corp (UTHR) (GuruFocus.com)
Jun-14-24 07:00PM	Insider Sale: Director Christopher Causey Sells Shares of United Therapeutics Corp (UTHR) (GuruFocus.com)
Jun-07-24 09:40AM	Why United Therapeutics (UTHR) is a Top Value Stock for the Long-Term (Zacks)
Jun-05-24 07:00AM	United Therapeutics Corporation to Present at the Goldman Sachs 45th Annual Global Healthcare Conference (Business Wire)
Jun-04-24 02:18PM	The 3 Most Undervalued Healthcare Stocks to Buy in June 2024 (InvestorPlace)
Jun-03-24 04:33PM	Liquidia Stock Surges After Winning Patent Battle Vs. United Therapeutics (Investor's Business Daily)
May-31-24 11:31AM	Why Is United Therapeutics (UTHR) Up 4.8% Since Last Earnings Report? (Zacks)
May-30-24 09:50AM	Here's Why United Therapeutics (UTHR) is a Strong Momentum Stock (Zacks)
May-27-24 10:11AM	3 Underappreciated Biotech Stocks to Buy Now: May 2024 (InvestorPlace)
May-23-24 09:45AM	Here's Why United Therapeutics (UTHR) is a Strong Growth Stock (Zacks)
May-22-24 09:40AM	Here's Why United Therapeutics (UTHR) is a Strong Value Stock (Zacks)
04:56AM	Latest 340B ruling delivers blow to providers (Healthcare Dive)
May-20-24 01:34PM	7 Biotech Stocks That Could Breathe New Life Into Your Portfolio (InvestorPlace)
May-16-24 07:01PM	Insider Sale: Director Christopher Causey Sells Shares of United Therapeutics Corp (UTHR) (GuruFocus.com)
07:01PM	Insider Sale: CFO and Treasurer James Edgemond Sells 40,160 Shares of United Therapeutics Corp ... (GuruFocus.com)
May-15-24 02:05AM	Q1 2024 Liquidia Corp Earnings Call (Thomson Reuters StreetEvents)
May-14-24 04:39PM	United Therapeutics Insider Sold Shares Worth $1,911,532, According to a Recent SEC Filing (MT Newswires)
May-10-24 04:41PM	United Therapeutics Insider Sold Shares Worth $1,898,393, According to a Recent SEC Filing (MT Newswires)
May-09-24 11:47AM	MannKind Corporation (NASDAQ:MNKD) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-08-24 05:15PM	United Therapeutics Insider Sold Shares Worth $949,737, According to a Recent SEC Filing (MT Newswires)
09:50AM	Why United Therapeutics (UTHR) is a Top Momentum Stock for the Long-Term (Zacks)
May-07-24 05:00PM	United Therapeutics Insider Sold Shares Worth $1,871,233, According to a Recent SEC Filing (MT Newswires)
02:23AM	Insider Sale: Director Judy Olian Sells Shares of United Therapeutics Corp (UTHR) (GuruFocus.com)
02:23AM	Insider Sale: Director Christopher Causey Sells Shares of United Therapeutics Corp (UTHR) (GuruFocus.com)
May-06-24 04:43PM	United Therapeutics Insider Sold Shares Worth $2,585,601, According to a Recent SEC Filing (MT Newswires)
02:30PM	3 Biotech Stocks to Double Your Money in the Next 24 Months (InvestorPlace)
12:45PM	United Therapeutics (UTHR) is an Incredible Growth Stock: 3 Reasons Why (Zacks)
09:45AM	Here's Why United Therapeutics (UTHR) is a Strong Growth Stock (Zacks)
09:15AM	United Therapeutics Corporation (UTHR) Hits Fresh High: Is There Still Room to Run? (Zacks)
May-05-24 08:19AM	Bright Horizons Family Solutions Inc. (NYSE:BFAM) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-03-24 07:50PM	Analyst Report: United Therapeutics Corporation (Morningstar Research)

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BENKOWITZ MICHAEL	PRESIDENT AND COO	Dec 09 '24	Option Exercise	107.00	10,000	1,069,995	4,500	Dec 10 04:32 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Dec 09 '24	Sale	367.69	10,000	3,676,877	0	Dec 10 04:32 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Dec 05 '24	Option Exercise	163.30	7,700	1,257,410	44,410	Dec 06 04:31 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Dec 05 '24	Sale	374.37	7,700	2,882,649	36,710	Dec 06 04:31 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Dec 02 '24	Option Exercise	104.33	10,000	1,043,325	7,500	Dec 03 04:30 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Dec 02 '24	Sale	370.51	10,000	3,705,074	0	Dec 03 04:30 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Nov 25 '24	Option Exercise	104.33	10,000	1,043,325	7,500	Nov 27 06:44 AM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Nov 25 '24	Sale	372.75	10,000	3,727,547	0	Nov 27 06:44 AM
MAHON PAUL A	EVP & GENERAL COUNSEL	Nov 21 '24	Option Exercise	163.30	7,700	1,257,410	44,410	Nov 22 05:37 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Nov 21 '24	Sale	367.36	7,700	2,828,672	36,710	Nov 22 05:37 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Nov 18 '24	Option Exercise	104.33	10,000	1,043,325	7,500	Nov 19 04:30 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Nov 18 '24	Sale	359.21	10,000	3,592,071	0	Nov 19 04:30 PM
Michael Benkowitz	Officer	Nov 18 '24	Proposed Sale	363.25	40,000	14,530,000		Nov 18 05:04 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Nov 11 '24	Option Exercise	104.33	15,000	1,564,988	11,250	Nov 12 04:30 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Nov 11 '24	Sale	407.32	15,000	6,109,841	0	Nov 12 04:30 PM
Olian Judy D.	Director	Nov 11 '24	Sale	412.48	1,750	721,840	5,655	Nov 12 04:30 PM
Mesa Nilda	Director	Nov 08 '24	Sale	412.28	224	92,350	5,783	Nov 12 04:30 PM
JUDY OLIAN	Director	Nov 11 '24	Proposed Sale	412.48	1,750	721,840		Nov 12 11:32 AM
MAHON PAUL A	EVP & GENERAL COUNSEL	Nov 07 '24	Option Exercise	163.30	7,700	1,257,410	44,410	Nov 08 04:30 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Nov 07 '24	Option Exercise	104.33	15,000	1,564,988	11,250	Nov 08 04:30 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Nov 06 '24	Option Exercise	112.50	10,000	1,125,000	7,500	Nov 08 04:30 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Nov 07 '24	Sale	401.44	15,000	6,021,620	0	Nov 08 04:30 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Nov 06 '24	Sale	394.96	10,000	3,949,594	0	Nov 08 04:30 PM
NILDA MESA	Director	Nov 08 '24	Proposed Sale	412.28	224	92,350		Nov 08 04:17 PM
Michael Benkowitz	Officer	Nov 06 '24	Proposed Sale	382.77	40,000	15,310,800		Nov 06 05:07 PM
Giltner Richard	Director	Nov 05 '24	Option Exercise	175.43	10,000	1,754,300	27,420	Nov 06 04:30 PM
Giltner Richard	Director	Nov 05 '24	Sale	381.70	10,000	3,817,022	17,420	Nov 06 04:30 PM
RICHARD GILTNER	Director	Nov 05 '24	Proposed Sale	381.70	10,000	3,817,022		Nov 05 04:33 PM
EDGEMOND JAMES	CFO AND TREASURER	Nov 04 '24	Option Exercise	118.99	8,334	991,622	10,912	Nov 05 04:30 PM
EDGEMOND JAMES	CFO AND TREASURER	Nov 04 '24	Sale	374.02	7,778	2,909,128	7,512	Nov 05 04:30 PM
CAUSEY CHRISTOPHER	Director	Nov 01 '24	Sale	376.63	510	192,080	3,675	Nov 04 04:30 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Nov 01 '24	Option Exercise	120.26	14,700	1,767,822	14,700	Nov 04 04:30 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Nov 01 '24	Sale	374.46	14,700	5,504,605	0	Nov 04 04:30 PM
JAMES EDGEMOND	Officer	Nov 04 '24	Proposed Sale	374.02	7,778	2,909,128		Nov 04 04:06 PM
CHRISTOPHER CAUSEY	Director	Nov 01 '24	Proposed Sale	376.63	510	192,080		Nov 01 04:45 PM
MICHAEL I BENKOWITZ REVOCABLE	Officer	Nov 01 '24	Proposed Sale	374.46	14,700	5,504,606		Nov 01 04:23 PM
EDGEMOND JAMES	CFO AND TREASURER	Oct 28 '24	Option Exercise	118.99	8,334	991,622	10,378	Oct 29 04:30 PM
EDGEMOND JAMES	CFO AND TREASURER	Oct 28 '24	Sale	350.00	7,800	2,730,000	6,978	Oct 29 04:30 PM
JAMES EDGEMOND	Officer	Oct 28 '24	Proposed Sale	350.00	7,800	2,730,000		Oct 28 04:13 PM
EDGEMOND JAMES	CFO AND TREASURER	Oct 21 '24	Option Exercise	118.99	8,334	991,622	9,826	Oct 22 04:30 PM
EDGEMOND JAMES	CFO AND TREASURER	Oct 21 '24	Sale	366.99	7,782	2,855,916	6,426	Oct 22 04:30 PM
JAMES EDGEMOND	Officer	Oct 21 '24	Proposed Sale	366.99	7,782	2,855,916		Oct 21 04:07 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Oct 03 '24	Option Exercise	163.30	7,700	1,257,410	44,410	Oct 18 05:19 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Oct 17 '24	Option Exercise	163.30	7,700	1,257,410	44,410	Oct 18 05:19 PM
EDGEMOND JAMES	CFO AND TREASURER	Oct 14 '24	Option Exercise	143.46	8,334	1,195,622	9,284	Oct 15 04:30 PM
EDGEMOND JAMES	CFO AND TREASURER	Oct 14 '24	Sale	355.88	7,792	2,773,017	5,884	Oct 15 04:30 PM
JAMES EDGEMOND	Officer	Oct 14 '24	Proposed Sale	355.88	7,792	2,773,017		Oct 15 08:19 AM
EDGEMOND JAMES	CFO AND TREASURER	Oct 07 '24	Option Exercise	118.99	8,334	991,622	8,744	Oct 08 04:30 PM
EDGEMOND JAMES	CFO AND TREASURER	Oct 07 '24	Sale	355.54	7,794	2,771,079	5,344	Oct 08 04:30 PM
EDGEMOND JAMES	CFO AND TREASURER	Sep 30 '24	Option Exercise	118.99	8,334	991,622	8,202	Oct 01 04:30 PM
EDGEMOND JAMES	CFO AND TREASURER	Sep 30 '24	Sale	358.62	7,792	2,794,367	4,802	Oct 01 04:30 PM
JAMES EDGEMOND	Officer	Sep 30 '24	Proposed Sale	358.62	7,792	2,794,367		Sep 30 04:04 PM
EDGEMOND JAMES	CFO AND TREASURER	Sep 23 '24	Option Exercise	118.99	8,334	991,622	7,664	Sep 24 04:30 PM
EDGEMOND JAMES	CFO AND TREASURER	Sep 23 '24	Sale	354.04	7,796	2,760,096	4,264	Sep 24 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Sep 19 '24	Option Exercise	163.30	7,700	1,257,410	44,410	Sep 23 04:30 PM
JAMES EDGEMOND	Officer	Sep 23 '24	Proposed Sale	354.04	7,796	2,760,096		Sep 23 04:02 PM
Olian Judy D.	Director	Sep 17 '24	Option Exercise	112.14	2,300	257,922	9,705	Sep 17 04:30 PM
EDGEMOND JAMES	CFO AND TREASURER	Sep 16 '24	Option Exercise	118.99	8,334	991,622	7,140	Sep 17 04:30 PM
EDGEMOND JAMES	CFO AND TREASURER	Sep 16 '24	Sale	339.12	7,810	2,648,527	3,740	Sep 17 04:30 PM
JUDY OLIAN	Director	Sep 17 '24	Proposed Sale	353.22	2,300	812,406		Sep 17 04:04 PM
JAMES EDGEMOND	Officer	Sep 16 '24	Proposed Sale	339.12	7,810	2,648,527		Sep 16 04:20 PM
EDGEMOND JAMES	CFO AND TREASURER	Sep 09 '24	Option Exercise	118.98	8,332	991,381	6,610	Sep 10 04:30 PM
EDGEMOND JAMES	CFO AND TREASURER	Sep 09 '24	Sale	345.41	7,802	2,694,889	3,210	Sep 10 04:30 PM
JAMES EDGEMOND	Officer	Sep 09 '24	Proposed Sale	345.41	7,802	2,694,889		Sep 09 04:14 PM
PATUSKY CHRISTOPHER	Director	Sep 04 '24	Option Exercise	175.43	4,300	754,349	5,200	Sep 05 04:30 PM
PATUSKY CHRISTOPHER	Director	Sep 03 '24	Option Exercise	175.43	700	122,801	1,600	Sep 05 04:30 PM
PATUSKY CHRISTOPHER	Director	Sep 04 '24	Sale	353.36	4,300	1,519,434	900	Sep 05 04:30 PM
PATUSKY CHRISTOPHER	Director	Sep 03 '24	Sale	360.31	700	252,214	900	Sep 05 04:30 PM
EDGEMOND JAMES	CFO AND TREASURER	Sep 03 '24	Option Exercise	118.98	8,332	991,381	6,015	Sep 04 04:34 PM
EDGEMOND JAMES	CFO AND TREASURER	Sep 03 '24	Sale	362.37	7,785	2,821,050	2,615	Sep 04 04:34 PM
CHRISTOPHER PATUSKY	Director	Sep 04 '24	Proposed Sale	353.36	4,300	1,519,434		Sep 04 04:14 PM
CHRISTOPHER PATUSKY	Director	Sep 03 '24	Proposed Sale	360.31	700	252,214		Sep 03 04:35 PM
JAMES EDGEMOND	Officer	Sep 03 '24	Proposed Sale	362.37	7,785	2,821,050		Sep 03 04:18 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Aug 26 '24	Option Exercise	129.49	269	34,833	399	Aug 28 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Aug 26 '24	Sale	348.41	269	93,723	130	Aug 28 04:30 PM
EDGEMOND JAMES	CFO AND TREASURER	Aug 26 '24	Option Exercise	118.98	8,332	991,381	5,482	Aug 26 04:30 PM
EDGEMOND JAMES	CFO AND TREASURER	Aug 26 '24	Sale	347.60	7,799	2,710,932	2,082	Aug 26 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Aug 22 '24	Option Exercise	129.49	3,600	466,164	3,730	Aug 26 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Aug 23 '24	Option Exercise	129.49	3,600	466,164	3,730	Aug 26 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Aug 23 '24	Sale	348.11	3,600	1,253,198	130	Aug 26 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Aug 22 '24	Sale	346.82	3,600	1,248,567	130	Aug 26 04:30 PM
JAMES EDGEMOND	Officer	Aug 26 '24	Proposed Sale	347.60	7,799	2,710,932		Aug 26 04:24 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Aug 20 '24	Option Exercise	129.49	3,600	466,164	3,730	Aug 22 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Aug 21 '24	Option Exercise	129.49	3,600	466,164	3,730	Aug 22 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Aug 21 '24	Sale	350.14	3,600	1,260,496	130	Aug 22 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Aug 20 '24	Sale	346.03	3,600	1,245,698	130	Aug 22 04:30 PM
CAUSEY CHRISTOPHER	Director	Aug 21 '24	Option Exercise	132.30	1,210	160,083	5,395	Aug 22 04:30 PM
CAUSEY CHRISTOPHER	Director	Aug 21 '24	Sale	349.00	1,210	422,290	4,185	Aug 22 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Aug 19 '24	Option Exercise	129.49	3,600	466,164	3,730	Aug 21 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Aug 19 '24	Sale	344.18	3,600	1,239,047	130	Aug 21 04:30 PM
CHRISTOPHER CAUSEY	Director	Aug 21 '24	Proposed Sale	349.00	1,210	422,290		Aug 21 04:05 PM
EDGEMOND JAMES	CFO AND TREASURER	Aug 19 '24	Option Exercise	118.98	8,332	991,381	4,978	Aug 20 04:30 PM
EDGEMOND JAMES	CFO AND TREASURER	Aug 19 '24	Sale	329.02	7,828	2,575,569	1,578	Aug 20 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Aug 15 '24	Option Exercise	129.49	3,600	466,164	3,730	Aug 19 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Aug 16 '24	Option Exercise	129.49	3,600	466,164	3,730	Aug 19 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Aug 15 '24	Sale	323.32	3,600	1,163,965	130	Aug 19 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Aug 16 '24	Sale	320.68	3,600	1,154,432	130	Aug 19 04:30 PM
JAMES EDGEMOND	Officer	Aug 19 '24	Proposed Sale	329.02	7,828	2,575,569		Aug 19 04:25 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Aug 13 '24	Option Exercise	129.49	3,600	466,164	3,730	Aug 15 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Aug 14 '24	Option Exercise	129.49	3,600	466,164	3,730	Aug 15 04:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

UTHR

United Therapeutics Corp

Upgrade your FINVIZ experience